이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RepliCel Life Sciences 관리

관리 기준 확인 3/4

RepliCel Life Sciences' CEO는 Andrew Schutte, Nov2022 에 임명되었습니다 의 임기는 1.58 년입니다. 는 CA$ 1.03M 가치에 해당하는 회사 주식의 26.77% 직접 소유합니다. 1.03M. 경영진과 이사회의 평균 재임 기간은 각각 1.6 년과 5.5 년입니다.

주요 정보

Andrew Schutte

최고 경영자

CA$8.9k

총 보상

CEO 급여 비율	n/a
CEO 임기	1.6yrs
CEO 소유권	26.8%
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

CEO

Andrew Schutte (34 yo)

1.6yrs

테뉴어

CA$8,917

보상

Mr. Andrew Schutte serves as President, Chief Executive Officer & Director of RepliCel Life Sciences Inc. since November 28, 2022. He served as an Independent Director of RepliCel Life Sciences Inc. since...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andrew Schutte	President	1.6yrs	CA$8.92k	26.77% CA$ 1.0m
Kevin McElwee	Co-Founder & Chief Scientific Officer	12.8yrs	CA$30.00k	2.04% CA$ 78.3k
Ben Austring	Chief Legal Officer	1.6yrs	CA$14.50k	0.49% CA$ 18.9k
Rolf Hoffmann	Chief Medical Officer & Member of Clinical Advisory Board	13.5yrs	데이터 없음	0.75% CA$ 28.8k
David Kwok	Chief Financial Officer	less than a year	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: RP 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Andrew Schutte	President	5.5yrs	CA$8.92k	26.77% CA$ 1.0m
Rolf Hoffmann	Chief Medical Officer & Member of Clinical Advisory Board	no data	데이터 없음	0.75% CA$ 28.8k
David Hall	Independent Chairman of the Board	13.5yrs	CA$17.75k	1.35% CA$ 51.6k
Jean Krutmann	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Ross Davidson	Chairman of Clinical Advisory Board	10.7yrs	데이터 없음	데이터 없음
Peter Lewis	Independent Director	13.1yrs	CA$14.45k	0.96% CA$ 36.9k
R. Buckler	Director	8.4yrs	CA$240.85k	0.010% CA$ 401.0
Gary Boddington	Independent Director	3yrs	CA$16.25k	0.48% CA$ 18.5k
Jamie MacKay	Director	less than a year	데이터 없음	15.44% CA$ 591.2k
Tsukasa Kumai	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Akimichi Morita	Member of Clinical Advisory Board	3.1yrs	데이터 없음	데이터 없음
Kunihiko Suzuki	Senior Strategic Advisor to Directors	2.7yrs	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: RP 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

RepliCel Life Sciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors

RepliCel Life Sciences Inc., Annual General Meeting, Sep 22, 2023

RepliCel Life Sciences Inc., Annual General Meeting, Feb 28, 2023

RepliCel Life Sciences Inc. Announces Executive Changes

RepliCel Life Sciences Inc., Annual General Meeting, Aug 24, 2022

Recent updates

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.031 loss in 3Q 2022)

First half 2023 earnings released: CA$0.028 loss per share (vs CA$0.054 loss in 1H 2022)

RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors

RepliCel Life Sciences Inc., Annual General Meeting, Sep 22, 2023

First quarter 2023 earnings released: CA$0.018 loss per share (vs CA$0.023 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.02 loss per share (vs CA$0.13 loss in FY 2021)

RepliCel Life Sciences Inc. announced that it has received CAD 0.01225 million in funding

RepliCel Life Sciences Inc. announced that it has received CAD 0.116419 million in funding

RepliCel Life Sciences Inc. announced that it has received $0.558837 million in funding

RepliCel Life Sciences Inc. announced that it has received CAD 0.841965 million in funding

RepliCel Life Sciences Inc., Annual General Meeting, Feb 28, 2023

Third quarter 2022 earnings released: CA$0.031 loss per share (vs CA$0.026 loss in 3Q 2021)

RepliCel Life Sciences Inc. Announces Executive Changes

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.8 million in funding

First half 2022 earnings released: CA$0.054 loss per share (vs CA$0.077 loss in 1H 2021)

RepliCel Life Sciences Inc. Receives Test Results Showing That Cells Injected Through the DermaPrecise

RepliCel Life Sciences Inc. Receives and Analyzes All Data and Images from Independent Laboratory Testing of the Dermaprecise Injector Prototype

RepliCel Life Sciences Inc., Annual General Meeting, Aug 24, 2022

RepliCel Life Sciences Inc. announced delayed 20-F filing

RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in funding from MainPointe Pharmaceuticals, LLC

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: CA$0.077 loss per share (vs CA$0.026 loss in 1H 2020)

RepliCel Life Sciences Inc. announced that it has received $0.16152 million in funding

RepliCel Life Sciences Inc. announced that it has received $0.111574 million in funding

Replicel Life Sciences Inc. Receiveds the First Units of Its Dermal Injector and Is Nearing Completion

Replicel Life Sciences Inc. Announces Record Year in Patents Granted

RepliCel Life Sciences Inc. announced delayed 20-F filing

Full year 2020 earnings released: CA$0.059 loss per share (vs CA$0.13 loss in FY 2019)

RepliCel Life Sciences Inc. announced that it has received CAD 0.492091 million in funding

New 90-day high: CA$0.33

RepliCel Life Sciences Inc. announced that it expects to receive CAD 2.7 million in funding from MainPointe Pharmaceuticals, LLC

New 90-day high: CA$0.24

First half earnings released

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.155645 million in funding

RepliCel Life Sciences Inc. announced that it expects to receive CAD 4 million in funding

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령